Pfizer posts positive Phase 3 results for LITFULO in vitiligo
FROM THE WIRE · FINANCE.YAHOO.COM
Pfizer (NYSE:PFE) reported Phase 3 results for oral LITFULO (ritlecitinib) in nonsegmental vitiligo, showing positive efficacy and safety outcomes. The late stage study found meaningful facial and total body repigmentation in treated patients, alongside a favorable tolerability…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPfizer achieved positive Phase 3 results for LITFULO in nonsegmental vitiligo, supporting immunology portfolio expansion.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01LITFULO (ritlecitinib) showed meaningful facial and total body repigmentation in Phase 3 study.
- 02LITFULO demonstrated a favorable tolerability profile in clinical trials.
- 03Pfizer plans to pursue regulatory submissions for LITFULO in vitiligo across multiple regions.
- 04Results support Pfizer's immunology portfolio expansion for systemic autoimmune skin condition treatments.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Pfizer Inc.28.13 USD+0.27%today +2.27%Positive Pfizer Inc24.87 EURMarket closedtoday +2.68%Positive Pfizer Inc24.83 EURMarket closedtoday +2.79%Positive
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets